Document Type

Journal Article

Publication Title

Journal of Bone and Mineral Research

Volume

40

Issue

3

First Page

323

Last Page

331

PubMed ID

39749990

Publisher

Oxford Academic

School

Nutrition and Health Innovation Research Institute / School of Medical and Health Sciences / Centre for Artificial Intelligence and Machine Learning (CAIML) / School of Science

Publication Unique Identifier

10.1093/jbmr/zjae208

RAS ID

76591

Funders

Rady Innovation Fund / Rady Faculty of Health Sciences / University of Manitoba / National Health and Medical Research Council of Australia / Medical Research Future Fund 2022 Cardiovascular Health Mission Grant (MRF2024225) / National Heart Foundation (107194, 107323) / Royal Perth Hospital Research Foundation Fellowship (RPHRF CAF 00/21) / Western Australian Future Health Research and Innovation Fund / Raine Medical Research Foundation

Grant Number

NHMRC Number : APP1183570

Comments

Smith, C., Sim, M., Ilyas, Z., Gilani, S. Z., Suter, D., Reid, S., ... & Leslie, W. D. (2025). Automated abdominal aortic calcification and major adverse cardiovascular events in people undergoing osteoporosis screening: The Manitoba Bone Mineral Density Registry. Journal of Bone and Mineral Research, 40(3), 323-331. https://doi.org/10.1093/jbmr/zjae208

Abstract

Vertebral fracture assessment (VFA) images from bone density machines enable the automated machine learning assessment of abdominal aortic calcification (ML-AAC), a marker of cardiovascular disease (CVD) risk. The objective of this study was to describe the risk of a major adverse cardiovascular event (MACE, from linked health records) in patients attending routine bone mineral density (BMD) testing and meeting specific criteria based on age, BMD, height loss, or glucocorticoid use have a VFA in the Manitoba BMD Registry. The cohort included 10 250 individuals (mean age 75.5 yr, 94% women without CVD) with VFA (February 2010 to March 2017). ML-AAC24 scores were categorized (low <2; moderate 2–<6; high ≥6). Over follow-up (mean 3.9 yr), 1265 people (12.3%) experienced a MACE. Among those with low, moderate, and high ML-AAC24, MACE rates per 1000 person-years were 18.4 (95% CI 16.4-20.5), 34.1 (95% CI 30.9-37.4), and 55.6 (95% CI 50.8-60.1), respectively. A similar gradient was observed after stratifying by age and sex. Incidence rate ratios (IRRs) for low vs moderate and high groups were 1.9 (95% CI 1.6-2.2) and 3.0 (95% CI 2.6-3.5), respectively. In those most likely to benefit from pharmaceutical intervention (<80 yr, not on statins), MACE rates among those with low, moderate, and high ML-AAC24 were 13.5 (95% CI 11.5-15.8), 26.0 (95% CI 22.1-30.3) and 44.1 (95% CI 37.0-52.0). Corresponding IRRs for low vs moderate 1.9 (95% CI 1.5-2.4) and high ML-AAC24 was 3.3 (95% CI 2.6-4.1]), respectively. In routine osteoporosis screening, individuals with moderate and high ML-AAC24 had substantially greater MACE rates compared to those with low ML-AAC24. Consequently, AAC detection during osteoporosis screening (especially in women) may guide intensification of preventative cardiovascular strategies.

DOI

10.1093/jbmr/zjae208

Creative Commons License

Creative Commons Attribution-Noncommercial 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

Included in

Epidemiology Commons

Share

 
COinS